LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(in thousands, except percentages)Three Months EndedJune 30,Variance20132012($)(%)(unaudited)RevenueTechnology and strategic partnerships
$31,148$29,565$1,5835%Assays and related products
54,28748,2736,01412%Operating income (loss)Technology and strategic partnerships
6,3947,290(896)-12%Assays and related products
(1,353)(804)(549)-68%Total Operating income (loss)
5,0416,486(1,445)-22%Six Months EndedJune 30,Variance20132012($)(%)(unaudited)RevenueTechnology and strategic partnerships
$63,017$59,774$3,2435%Assays and related products
107,48797,00010,48711%Operating income (loss)Technology and strategic partnerships
14,07514,520(445)-3%Assays and related products
(10,586)(2,426)(8,160)-336%Total Operating income (loss)
FINANCIAL OUTLOOK AND GUIDANCE The Company reaffirms its 2013 annual revenue guidance of between $220 and $230 million although we expect a challenging reimbursement environment near-term for select molecular diagnostic tests that could weigh on overall corporate performance, as considered in the lower end of this revenue range.
CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2013, on Monday, July 29, 2013, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time. The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to th
|SOURCE Luminex Corporation|
Copyright©2012 PR Newswire.
All rights reserved